|
[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Feng, R.M., Zong, Y.N., Cao, S.M. and Xu, R.H. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications, 39, 1-12. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ben-son III, A.B., Venook, A.P., Cederquist, L., et al. (2017) Colon Cancer, Version 1.2017, NCCN Clinical Practice Guide-lines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 370-398. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Dekker, E., Tanis, P.K., Vleugels, J.L.A. and Kasi, P.M. (2019) Colorectal Cancer. The Lancet, 394, 1467-1480. [Google Scholar] [CrossRef]
|
|
[6]
|
Degro, C.E., Strozynski, R., Loch, F.N., et al. (2021) Sur-vival Rates and Prognostic Factors in Right- and Left-Sided Colon Cancer Stage I-IV: An Unselected Retrospective Sin-gle-Center Trial. International Journal of Colorectal Disease, 36, 2683-2696. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Dienstmann, R., Vermeulen, L., Guinney, J., et al. (2017) Con-sensus Molecular Subtypes and the Evolution of Precision Medicine in Colorectal Cancer. Nature Reviews Cancer, 17, 79-92. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Manes, M., Garcia-Gomes, M.S.A., Sandini, T.M., et al. (2019) Behavioral and Neurochemical Characterization of the mlh Mutant Mice Lacking Otoconia. Behavioural Brain Research, 359, 958-966. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Cai, Y., Rattray, N.J.W., Zhang, Q., et al. (2020) Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. Scientific Reports, 10, Article No. 4905. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
De Renzi, G., Gaballo, G., Gazzaniga, P. and Nicolazzo, C. (2021) Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New In-sights. Oncology, 99, 135-143. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Holch, J.W., Ricard, I., Stintzing, S., et al. (2017) The Relevance of Pri-mary Tumour Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials. Eu-ropean Journal of Cancer, 70, 87-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Arnold, D., Lueza, B., Douillard, J.Y., et al. (2017) Prognostic and Predictive Value of Primary Tumour Side in Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Chemotherapy and EGFR Directed Antibodies in Six Randomized Trials. Annals of Oncology, 28, 1713-1729. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zhao, B., Wang, L., Qiu, H., et al. (2017) Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer. Oncotarget, 8, 3980-4000. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Nam, S.K., Yun, S., Koh, J., et al. (2016) BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metas-tasis. PLOS ONE, 11, e0151865. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Zhao, B., Lopez, N.E., Eisenstein, S., et al. (2020) Synchro-nous Metastatic Colon Cancer and the Importance of Primary Tumor Laterality—A National Cancer Database Analysis of Right- versus Left-Sided Colon Cancer. The American Journal of Surgery, 220, 408-414. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Petrelli, F., Tomasello, G., Borgonovo, K., et al. (2017) Prog-nostic Survival Associated with Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-Analysis. JAMA Oncology, 3, 211-219. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Laghi, L., Negri, F., Gaiani, F., et al. (2020) Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer. International Journal of Molecular Sciences, 21, Article No. 9680. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Yi, T., Zhang, Y., Ng, D.M., et al. (2021) Regulatory Network Analy-sis of Mutated Genes Based on Multi-Omics Data Reveals the Exclusive Features in Tumor Immune Microenvironment between Left-Sided and Right-Sided Colon Cancer. Frontiers in Oncology, 11, Article ID: 685515. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Wang, X., Duanmu, J., Fu, X., Li, T. and Jiang, Q. (2020) Ana-lyzing and Validating the Prognostic Value and Mechanism of Colon Cancer Immune Microenvironment. Journal of Translational Medicine, 18, 324. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Li, X.Y., Wen, D.C., Li, X.K., et al. (2020) Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer. Frontiers in Immunology, 11, Article No. 1678. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Cheng, Y., Ling, Z. and Li, L. (2020) The Intestinal Microbiota and Colorectal Cancer. Frontiers in Immunology, 11, Article ID: 615056. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Rubinstein, M.R., Wang, X., Liu, W., et al. (2013) Fusobacte-rium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via Its FadA Adhe-sin. Cell Host & Microbe, 14, 195-206. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Casasanta, M.A., Yoo, C.C., Udayasuryan, B., et al. (2020) Fusobacterium nucleatum Host-Cell Binding and Invasion Induces IL-8 and CXCL1 Secretion that Drives Colorectal Cancer Cell Migration. Science Signaling, 13, eaba9157. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Cuevas-Ramos, G., Petit, C.R., Marcq, I., et al. (2010) Escherichia coli Induces DNA Damage in Vivo and Triggers Genomic Instability in Mammalian Cells. Proceedings of the National Academy of Sciences of the United States of America, 107, 11537-11542. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Sears, C.L. and Pardoll, D.M. (2011) Perspective: Alpha-Bugs, Their Microbial Partners, and the Link to Colon Cancer. The Journal of Infectious Diseases, 203, 306-311. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Tjalsma, H., Boleij, A., Marchesi, J.R. and Dutilh, B.E. (2012) A Bacte-rial Driver-Passenger Model for Colorectal Cancer: Beyond the Usual Suspects. Nature Reviews Microbiology, 10, 575-582. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Alhinai, E.A., Walton, G.E. and Commane, D.M. (2019) The Role of the Gut Microbiota in Colorectal Cancer Causation. International Journal of Molecular Sciences, 20, Article No. 5295. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Phipps, O., Quraishi, M.N., Dickson, E.A., et al. (2021) Differ-ences in the On- and Off-Tumor Microbiota between Right- and Left-Sided Colorectal Cancer. Microorganisms, 9, 1108. [Google Scholar] [CrossRef]
|
|
[29]
|
Zhong, M., Xiong, Y., Ye, Z., et al. (2020) Microbial Community Profiling Distinguishes Left-Sided and Right-Sided Colon Cancer. Frontiers in Cellular and Infection Microbiology, 10, Article ID: 498502. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Bach, S., Sluiter, N.R., Beagan, J.J., et al. (2019) Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. JNCI Cancer Spec-trum, 3, pkz042. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Nicolazzo, C., Raimondi, C., Gradilone, A., et al. (2019) Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer. Cancers, 11, Article No. 1042. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Taniguchi, H., Nakamura, Y., Kotani, D., et al. (2021) CIRCULATE-Japan: Circulating Tumor DNA-Guided Adaptive Platform Trials to Refine Adjuvant Therapy for Colo-rectal Cancer. Cancer Science, 112, 2915-2920. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Kishiki, T., Kuchta, K., Matsuoka, H., et al. (2019) The Impact of Tumor Location on the Biological and Oncological Differences of Colon Cancer: Multi-Institutional Propensity Score-Matched Study. The American Journal of Surgery, 217, 46-52. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Di Buono, G., Buscemi, S., Cocorullo, G., et al. (2021) Feasibility and Safety of Laparoscopic Complete Mesocolic Exci-sion (CME) for Right-Sided Colon Cancer: Short-Term Outcomes. A Randomized Clinical Study. Annals of Surgery, 274, 57-62. [Google Scholar] [CrossRef]
|
|
[35]
|
Yang, L., Xiong, Z., Xie, Q., et al. (2018) Prognostic Value of Total Number of Lymph Nodes Retrieved Differs between Left-Sided Colon Cancer and Right-Sided Colon Cancer in Stage III Patients with Colon Cancer. BMC Cancer, 18, Article No. 558. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Cai, Y., Cheng, G., Lu, X., Ju, H. and Zhu, X. (2020) The Re-Evaluation of Optimal Lymph Node Yield in Stage II Right-Sided Colon Cancer: Is a Minimum of 12 Lymph Nodes Adequate? International Journal of Colorectal Disease, 35, 623-631. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Lee, L., Erkan, A., Alhassan, N., et al. (2018) Lower Survival after Right-Sided Versus Left-Sided Colon Cancers: Is an Extended Lymphadenectomy the Answer? Surgical Oncology, 27, 449-455. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Benson III, A.B., Venook, A.P., Al-Hawary, M.M., et al. (2021) Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Com-prehensive Cancer Network, 19, 329-359. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Neugut, A.I., Lin, A., Raab, G.T., et al. (2019) FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clinical Colorectal Cancer, 18, 133-140. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Fong, Y. (1999) Surgical Therapy of Hepatic Colorectal Metasta-sis. CA: A Cancer Journal for Clinicians, 49, 231-255. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Teo, J.Y., Allen, J.C., Ng, D.C., et al. (2016) A Systematic Review of Contralateral Liver Lobe Hypertrophy after Unilobar Selective Internal Radiation Therapy with Y90. HPB, 18, 7-12. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Ruers, T., Van Coevorden, F., Punt, C.J.A., et al. (2017) Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. Journal of the National Cancer Institute, 109, djx015. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Lévi, F.A., Boige, V., Hebbar, M., et al. (2016) Conversion to Resection of Liver Metastases from Colorectal Cancer with Hepatic Artery Infusion of Combined Chemotherapy and Systemic Ce-tuximab in Multicenter Trial OPTILIV. Annals of Oncology, 27, 267-274. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Garajova, I., Balsano, R., Tommasi, C., et al. (2020) Synchronous and Metachronous Colorectal Liver Metastases: Impact of Primary Tumor Location on Patterns of Recurrence and Sur-vival after Hepatic Resection. Acta Biomedica, 92, e2021061.
|
|
[45]
|
Colloca, G.A., Venturino, A. and Guarneri, D. (2020) Different Variables Predict the Outcome of Patients with Synchronous versus Metachronous Metastases of Colorectal Cancer. Clinical and Translational Oncology, 22, 1399-1406. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Kafatos, G., Banks, V., Burdon, P., et al. (2021) Impact of Bi-omarkers and Primary Tumor Location on the Metastatic Colorectal Cancer First-Line Treatment Landscape in five Euro-pean Countries. Future Oncology, 17, 1495-1505. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Yoshino, T., Amold, D., Taniguchi, H., et al. (2018) Pan-Asian Adapted ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer: A JSMO-ESMO Initiative Endorsed by CSCO, KACO, MOS, SSO and TOS. Annals of Oncology, 29, 44-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
You, X.H., Jiang, Y.H., Fang, Z., et al. (2020) Chemotherapy Plus Bevacizumab as an Optimal First-Line Therapeutic Treatment for Patients with Right-Sided Metastatic Colon Cancer: A Meta-Analysis of First-Line Clinical Trials. ESMO Open, 4, e000605. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Temraz, S., Mukherji, D., Nassar, F., et al. (2021) Treatment Sequencing of Metastatic Colorectal Cancer Based on Primary Tumor Location. Seminars in Oncology, 48, 119-129. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Chibaudel, B., André, T., Tournigand, C., et al. (2020) Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study. Clinical Colorectal Cancer, 19, 200-208.E1. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Pietrantonio, F., Petrelli, F., Coinu, A., Ghilardi, M., et al. (2015) Predictive Role of BRAF Mutations in Patients with Advanced Colorectal Cancer Receiving Cetuximab and Pani-tumumab: A Meta-Analysis. European Journal of Cancer, 51, 587-594. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Innocenti, F., Ou, F.S., Qu, X., et al. (2019) Mutational Analysis of Patients with Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tu-mor Mutational Burden for Patient Outcome. Journal of Clinical Oncology, 37, 1217-1227. [Google Scholar] [CrossRef]
|
|
[53]
|
Cremolini, C., Loupakis, F., Antoniotti, C., et al. (2015) FOLFOXIRI Plus Bevacizumab versus FOLFIRI Plus Bevacizumab as First-Line Treatment of Patients with Metastatic Colorectal Cancer: Updated Overall Survival and Molecular Subgroup Analyses of the Open-Label, Phase 3 TRIBE Study. The Lancet Oncology, 16, 1306-1315. [Google Scholar] [CrossRef]
|
|
[54]
|
Ducreux, M., Chamseddine, A., Laurent-Puig, P., et al. (2019) Molecular Targeted Therapy of BRAF-Mutant Colorectal Cancer. Therapeutic Advances in Medical Oncology, 11, Article ID: 1758835919856494. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Bao, X., Zhang, H., Wu, W., et al. (2020) Analysis of the Mo-lecular Nature Associated with Microsatellite Status in Colon Cancer Identifies Clinical Implications for Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e001437. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
André, T., Shiu, K.K., Kim, T.W., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England Journal of Medicine, 383, 2207-2218. [Google Scholar] [CrossRef]
|
|
[57]
|
Overman, M.J., McDermott, R., Leach, J.L., et al. (2017) Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study. The Lancet Oncology, 18, 1182-1191. [Google Scholar] [CrossRef]
|
|
[58]
|
Overman, M.J., Lonardi, S., Wong, K.Y.M., et al. (2018) Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instabil-ity-High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 36, 773-779. [Google Scholar] [CrossRef]
|
|
[59]
|
Picard, E., Verschoor, C.P., Ma, G.W. and Pawelec, G. (2020) Relationships between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 11, Article No. 369. [Google Scholar] [CrossRef] [PubMed]
|